The Healthy Aging Company

DEVELOPING GAME CHANGER THERAPIES FOR
Diabetes Type 2 Diseases and its related complications such as Diabetic Neuropathy and Alzheimer's disease.

High level
Scientific Publications


THAC, The Healthy Aging Company, is a French and US-based privately-owned biopharmaceutical company which has the ambition to develop a range of first-in-class drug candidates targeting T2DM and its complications.

Pre-clinical and clinical data of ALF-5755 published in international peer-review
 
♦ The co-founders of THAC have a track record in scientific publications with more than 500 altogether. Pr Christian Bréchot is a worldwide renowned scientific. Pr Christian Magnan has published more than 130 scientific publications in the metabolism / diabetes field.

♦ In the context of THAC, the unique and innovative mechanism of action of ALF-5755 and all its scientific and clinical results already observed are the object of publications by the founders in high level scientific journals.

♦ Below are the latest publications regarding ALF-5755 and its mechanism of action in the context of T2DM: anti-inflammatory, antioxidant, insulin sensitizer, restoration of the microbiota composition.

The latest scientific publications regarding ALF-5755 (HIP/PAP, alpha-Reg3)

♦ Le Lay, A., Philippe, E., Roth, F., Sanchez-Archidona, A. R., Mehl, F., Denom, J., Prasad, R., Asplund, O., Hansson, O., Ibberson, M., Andreelli, F., Santoro, L., Amouyal, P., Amouyal, G., Brechot, C., Jamot, L., Cruciani-Guglielmacci, C., & Magnan, C. (2022). Regenerating islet-derived protein 3α : A promising therapy for diabetes. Preliminary data in rodents and in humans. Heliyon8(7), e09944

 Darnaud M, Dos Santos A, Gonzalez P, Agui S, Lacoste C, Detercke C, De Hertogh G, Valentino E, Bran E, Zheng J, Boisgard R, Neut C, Dubuquoy L, Chiappini F, Samuel D, Lepage P, Guerrieri F, Doré J, Bréchot C, Moniaux N, Faivre J- « Enteric delivery of regeneraing family member 3 apha-Reg alters the intestinal microbiota and controls inflammation in mice with colitis » Gastroenterology 2018 154 (1000).

♦ Nalpas B, Ichaï P, Jamot L, Carbonell N, Rudler M, Mathurin P, Durand F, Gerken G, Manns M, Trautwein C, Larrey D, Radenne S, Duvoux C, Leroy V, Bernuau J, Faivre J, Moniaux N, Bréchot C, Amouyal G, Amouyal P, Samuel D-  « A Proof of Concept, Phase II Randomized European Trial, on the Efficacy of ALF-5755, a Novel Extracellular Matrix-Targeted Antioxidant in Patients with Acute Liver Diseases ». PLoS One. 2016 Mar 16;11(3).

 Haldipur P, Dupuis N, Degos V, Moniaux N, Chhor V, Rasika S, Schwendimann L, le Charpentier T, Rougier E, Amouyal P, Amouyal G, Dournaud P, Bréchot C, El Ghouzzi V, Faivre J, Fleiss B, Mani S, Gressens P – « HIP/PAP prevents excitoxic neuronal death and promotes plasticity ». Ann Clin Transl Neurol. 2014 Oct;1(10):739-54.

♦ Nicolas Moniaux, Marion Darnaud, Kévin Garbin, Alexandre Dos Santos, Catherine Guettier, Didier Samuel, Gilles Amouyal, Paul Amouyal, Christian Bréchot, Jamila Faivre- « The Reg3α (HIP/PAP) Lectin Suppresses Extracellular Oxidative Stress in a Murine Model of Acute Liver Failure ». PLoS One. 2015 May 4;10(5).

 Moniaux N, Song H, Darnaud M, Garbin K, Gigou M, Mitchell C, Samuel D, Jamot L, Amouyal P, Amouyal G, Bréchot C, Faivre J. Human – « hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein cures fas-induced acute liver failure in mice by attenuating free-radical damage in injured livers ». Hepatology. 2011 Feb;53(2):618-2.

 Lieu HT, Batteux F, Simon FT, Cortes A, Nicco C, Zavata F, Pauoin A., Trahao JG, Soubrane O, Weill B, Bréchot C, Christa – « HIP/PAP accelerates liver regeneration andprotects against acetaminophren injury in mice » – Hepatology 2005.